AVISCERA BIOSCIENCE  
AVISCERA BIOSCIENCE  
line decor
  HOME  ::  
line decor
   
 

Tumor Necrosis Factor (TNF)-Related Apoptosis-Inducing Ligand (TRAIL)  ELISA KIT

  • CD253
  • TNFSF10
  • TRAIL
  • APO2L

The effect of exercise on osteoprotegerin and TNF-related apoptosis-inducing ligand in obese patients

Background  Biomarkers of cardiovascular (CV) risk are tests that predict a patient's risk of future CV events. Recently, two proteins involved in vascular calcification; serum levels of osteoprotegerin (OPG) and tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) have emerged as potentially useful biomarkers. OPG levels are positively correlated with CV risk, whereas TRAIL levels show a negative correlation. Exercise training is known to reduce risk factors for CV disease by improving metabolism, vascular biology and blood flow. This study examined the effects of a 6-month exercise training programme on levels of OPG and TRAIL. Pulse wave velocity (PWV) and high-sensitivity C-reactive protein (hsCRP) were measured for comparative purposes. Materials and methods  Overweight and obese patients undertook a 6-month exercise programme. Patients participated in 4 h of primarily aerobic exercise per week of which 2 h were supervised. At the beginning and end of the programme, anthropometric measurements, PWV and serum levels of OPG, TRAIL and hsCRP were measured. Results  A total of 21 patients (17 men) aged 55·2 ± 10 years completed the programme. Mean body mass index decreased from 34·1 ± 5·8 to 32·6 ± 5·4 kg/m(2) (P < 0·05), while waist circumference decreased from 111·8 ± 12·4 to 109·6 ± 12·8 cm (P < 0·05). PWV decreased from 9·2 to 8·5 m/s (P < 0·02). OPG, TRAIL and hsCRP levels did not change significantly. Conclusions  Exercise training reduced PWV but not OPG, TRAIL or hsCRP in this population. These data suggest that while an intervention of this nature improves vascular tone, it does not exert significant effects onserum biomarkers related to atherosclerotic inflammation and calcification.
Davenport C,  et al. Eur J Clin Invest. 2012 Jun 18. doi: 10.1111/j.1365-2362.2012.02703.x. [Epub ahead of print]

Clinical significance of TRAIL and TRAIL receptors in patients with head and neck cancer

BACKGROUND:Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a death ligand currently under clinical trials for cancer. The molecular profile of TRAIL and TRAIL receptors has not yet been mapped for patients with laryngeal squamous cell carcinoma (SCC) or patients with oral cavity squamous cell carcinoma (OCSCC).
METHODS:Paraffin-embedded tissues from 60 patients with laryngeal SCC and 14 patients with OCSCC were retrospectively analyzed using immunohistochemistry.
RESULTS:An increase in decoy-R1 (DcR1) but a decrease in decoy-R2 (DcR2) expression were observed in patients with laryngeal SCC and in patients with OCSCC compared with control individuals with benign lesions. Clinical and pathologic grading revealed distinctive TRAIL and TRAIL receptor profiles in patients with squamous cell carcinoma of the head and neck (SCCHN).
CONCLUSIONS:TRAIL and a TRAIL receptor expression profile might be useful to follow-up disease progression by virtue of its connection with clinical staging and pathologic grading in patients with laryngeal SCC.
Yoldas B, , et al. Head Neck. 2011 Sep;33(9):1278-84. doi: 10.1002/hed.21598. Epub 2010 Nov 10.

Aberrant expression and function of death receptor-3 and death decoy receptor-3 in human cance

Death receptor-3 (DR3) and death decoy receptor-3 (DcR3) are both members of the tumour necrosis factor receptor (TNFR) superfamily. The TNFR superfamily contains eight death domain-containing receptors, including TNFR1 (also called DR1), Fas (also called DR2), DR3, DR4, DR5, DR6, NGFR and EDAR. Upon the binding of these receptors with their corresponding ligands, the death domain recruits various proteins that mediate both the death and proliferation of cells. Receptor function is negatively regulated by decoy receptors (DcR1, DcR2, DcR3 and OPG). DR3/DcR3 are a pair of positive and negative players with which vascular endothelial growth inhibitor (VEGI) interacts. VEGI has been suggested to be a potential tumour suppressor. The inhibitory effects of VEGI on cancer are manifested in three main areas: a direct effect on cancer cells, an anti-angiogenic effect on endothelial cells, and the stimulation of dendritic cell maturation. A recent study indicated that DR3 may be a new receptor for E-selectin, which has been reported to be associated with cancer metastasis. DcR3 is a soluble receptor, highly expressed in various tumours, which lacks an apparent transmembrane segment, prevents cytokine response through ligand binding and neutralization, and is an inhibitor of apoptosis. DcR3 serves as a decoy receptor for FasL, LIGHT and VEGI. The cytokine LIGHT activates various anti-tumour functions and is expected to be a promising candidate for cancer therapy. Certain tumours may escape FasL-dependent immune-cytotoxic attack by expressing DcR3, which blocks FasL function. DR3/DcR3 play profound roles in regulating cell death and proliferation in cancer. The present review briefly discusses DR3/DcR3 and attempts to elucidate the role of these negative and positive players in cancer.
Ge Z et al. . Exp Ther Med. 2011 Mar;2(2):167-172. Epub 2011 Jan 20. .
 
human soluble trail elisa kit from aviscera bioscience
Human Soluble TRAILELISA Kit
Code No.: SK00252-01
Size: 96 T
Price: $360.00 USD
Standard Range:15-1000 p g/mL
Sensitivity:10 pg/ml
Sample Type: cell cultures, serum, plasma
Sample require: 240 uL
Intra-CV: 4-8%
Inter-CV: 6-10
Protocol: PDF
Human Soluble TRAILELISA Kit
Code No.: SK00252-02
Size: 96 T
Price: $360.00 USD
Standard Range:62-4000 p g/mL
Sensitivity:20 pg/ml
Sample Type: cell cultures, serum, plasma
Sample require: 240 uL
Intra-CV: 4-8%
Inter-CV: 6-10
Protocol: PDF
  Human Soluble TRAIL R3 ELISA Kit
Code No.: SK00253-01
Size: 96 T
Price: $360.00 USD
Standard Range:31-2000 p g/mL
Sensitivity:10 pg/ml
Sample Type: cell cultures, serum, plasma
Sample require: 240 uL
Intra-CV: 4-8%
Inter-CV: 6-10
Protocol: PDF
Human Soluble TRAIL R4/DcR2 ELISA Kit
Code No.: SK00254-01
Size: 96 T
Price: $360.00 USD
Standard Range:62.5-4000 p g/mL
Sensitivity:20 pg/ml
Sample Type: cell cultures, serum, plasma
Sample require: 240 uL
Intra-CV: 4-8%
Inter-CV: 6-10
Protocol: PDF
Name
Code No.
Size
Price ($)
Human Soluble TRAIL (Human) ELISA Kit
96 T
360.00
Human Soluble TRAIL (Human) ELISA Kit
96 T
360.00
Human Soluble TRAIL R3 (Human) ELISA Kit
96 T
360.00
Human Soluble DcR2/TRAIL R4 (Human) ELISA Kit
96 T
360.00